
Complete "Sample-to-Result" Highly Automated NGS and qPCR **Workflow for Clinical Diagnostics**

Elian Rakhmanaliev, Tatiana Ivanova, Yin Kum Ng, Alex Yeo, Harry Suhardi, Caroline Villy, Mei Qi Yee, Kevin Tan, Amanda Fan, Andy Soh, Pramila Ariyarathe, Si Kee Tan, Jocelyn Wong, Jiang Xia, Grace Tan, Jasmin Ang, John Ong, Charlie Lee, Gerd Michel, Wen Huang.

Vela Research Singapore Pte. Ltd., Singapore.

INTRODUCTION

Sanger sequencing and real-time PCR methods have been the standard molecular methods in clinical diagnostics for decades. Deep sequencing or Next Generation Sequencing (NGS) technology revolutionized the field of genomics, transcriptomics and metagenomics and is now rapidly becoming a routine method in different areas of clinical diagnostics such virology, oncology, drug-resistance monitoring, non-invasive prenatal tests, microbiology, precision medicine, etc. [1,2].





& NGS 2017 3rd - 7th April 2017 & Workshops & Exhibition Liquid Biopsy, Integrative Big Data Analysis Biomarker Signature ... and beyond @TUM, Freising-Weihenstephan, Germa

RESULTS

Vela Diagnostics developed a complete ("Sample-to-Result") highly automated multi-purpose *Sentosa* workflow, which consists of:

- 1. A robotic liquid handling system for nucleic acid extraction, PCR set-up and/or NGS library preparation (*Sentosa* SX101);
- Instruments for real-time PCR or template preparation and deep 2. sequencing (Ion Torrent's PGM system);
- Kits for nucleic acid extraction, target specific real-time PCR-based 3. tests, NGS library preparation assays and deep sequencing;
- Assay specific applications; 4.
- Data analysis and reporting software. 5.

Different diagnostic applications employ the same robotic platform for qPCR set-up and preparation of NGS libraries. In less than 5 years Vela Diagnostics developed 7 NGS-based viral and oncology assays and more than 20 qPCR-based viral, microbial and oncology CE-IVD tests, which can be run on the same system. In addition, several extraction kits were developed to isolate nucleic acids from various types of clinical samples, including FFPE, whole blood, plasma/serum, swabs, stool, etc. (Table).

Figure 2. Vela Diagnostics *Sentosa*[®] qPCR Workflow.

Vela Diagnostics qPCR workflow (Fig. 2) allows for nucleic acid extraction and PCR setup on various sample types (Table) with run throughput ranging from 8 to 96 samples. With more than 20 available tests covering applications for Immunosuppression, Virology, Oncology and Gastroenteritis, the flexibility of the platform allows for a wide selection of menu.

Using the same robotic system (Sentosa[®] SX101) as the NGS workflow, it enables both NGS and qPCR workflows to be performed on a relatively small laboratory footprint. The PCR tests are compatible with the Sentosa® SA201 (Applied Biosystems) or the Rotor-Gene Q (QIAGEN). Customized color coded reagent tube holders allows for easy placement of PCR reagents on the robotic deck. Sample traceability and instruments connectivity is seamlessly maintained through the network with Vela Diagnostics customized robotics and instrument software. Automatic analysis and reporting of qPCR results is available with the SA Reporter software, providing integrated solution for sample to results within 3-4 hrs.




Figure 1. Vela Diagnostics *Sentosa*[®] NGS Workflow.

Sample Type	Extraction Throughput
Throat, Wound, Perianal, Rectal and Nasal swabs, Stool	8 – 96 Samples
Whole Blood, Serum, Plasma, Sputum, Swab in UTM, Cerebrospinal fluid (CSF), Urine	8 – 24 Samples
Formalin-fixed, paraffin-embedded (FFPE)	8 – 16 Samples

Integration with *Sentosa®* Link middleware connects the system to the laboratory network and ensures sample traceability. Highly automated extraction, PCR set-up and NGS libraries preparation in conjunction with fully automated data analysis and reporting system reduce hands-on time up to 0.5 hrs. for the PCR and 3.5 hrs. for the NGS tests. The flexibility of the PCR platform allows for consolidated testing with more than 20 PCR tests

Vela Diagnostics NGS workflow (Fig. 1) provides solution for both Oncology and Virology samples using the customized instruments from Eppendorf (Sentosa[®] SX101) and Ion Torrent (Sentosa[®] SQ301). The flexibility in pipetting programs of the *Sentosa*[®] SX allows for 8 (Oncology) or 16 (Virology) barcoded libraries to be processed on deck. Dedicated reagents for nucleic acid extraction and library preparation are supplied for simplicity to the user.

The Sentosa[®] ST401 and SQ301 by Ion Torrent performs clonal emulsion amplification and sequencing respectively. The use of semiconductor sequencing technology allows for targeted sequencing workflow to be performed in a relatively short amount of time. Sample traceability and instruments connectivity is maintained through the network with Vela Diagnostics customized software. Automatic data analysis and reporting of genotypes and mutations is available with the SQ Reporter software, providing integrated solution for sample to results within 2 days.

and 14 clinically relevant and validated human sample types.

CONCLUSION

Sentosa qPCR and NGS workflow appears as a robust and efficient in vitro diagnostics (IVD) tool for the detection and/or quantitation of a wide range of bacterial and viral pathogens as well as mutations in human genes. Such comprehensive combined NGS and qPCR workflow that can help fill some existing gaps in the quality of molecular diagnostics will take the necessary steps towards improving patient outcomes.



1) *Lefterova M. et al.* J. Mol. Diagn. 2015, 17: 623-634 2) *Barson L. et al*. J. Clin. Virol. 2013, 58: 346-350

www.veladx.com